EXTENDED REPORT

Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma

M Emre, S Orgül, T Haufschil, S G Shaw, J Flammer

Aim: To compare the plasma levels of endothelin-1 (ET-1) between patients with primary open angle glaucoma with visual field progression despite normal or normalised intraocular pressure and patients with stable visual fields in a retrospective study.

Methods: The progressive group consisted of 16 primary open angle glaucoma patients and the group with stable visual field consisted of 15 patients. After a 30 minute rest in a supine position, venous blood was obtained for ET-1 dosing. Difference in the plasma level of ET-1 between two groups was compared by means of analysis of covariance (ANCOVA), including age, sex, and mean arterial blood pressure as covariates.

Results: ET-1 plasma levels were found to be significantly increased in patients with deteriorating (3.47 (SD 0.75) pg/ml) glaucoma when compared to those with stable (2.59 (SD 0.54) pg/ml) visual fields (p = 0.0007).

Conclusions: Glaucoma patients with visual field progression in spite of normal or normalised intraocular pressure have been found to have increased plasma endothelin-1 levels. It remains to be determined if this is a secondary phenomenon or whether it may have a role in the progression of glaucomatous damage.

Increased plasma ET-1 levels have been described in normal tension glaucoma patients, although this was not confirmed in all studies with normal tension glaucoma patients or in studies with high tension glaucoma patients.

The fact that aqueous ET-1 concentration is increased in primary open angle glaucoma and in animal models of glaucoma underscores the possible contribution of endothelin to the pathogenesis of primary open angle glaucoma. Furthermore, chronic administration of ET-1 has been shown to produce an optic neuropathy similar to glaucoma.

Because an active role of ET-1 in POAG would suppose a higher level in patients with active disease, we compared the plasma levels of ET-1 in POAG patients with progressive visual field deterioration to POAG patients with a stable damage.

PATIENTS AND METHODS

This study adhered to the tenets of the Declaration of Helsinki and was approved by the local ethics committee. Informed consent for the use of their clinical data in a scientific publication was obtained from each patient. Thirty one primary open angle glaucoma patients (seven men and 24 women), including normal tension glaucoma patients, were selected. Patients with closed iridocorneal angles, evidence of secondary glaucoma, pseudoexfoliation, pigmented dispersion, a history of intraocular surgery (except for filtration surgery), any form of retinal or neuroophthalmologic disease that could result in visual field defects, or with a history of chronic systemic medication or disease, especially diabetes mellitus, systemic hypertension, occlusive vascular disorders, chronic heart failure, renal failure, glomerulonephritis, and autoimmune diseases, were not included.

Eyes had to have a visual acuity of 20/30 or better and no clinical evidence of opacity of the media (nuclear sclerotic cataract, or the development of any degree of posterior subcapsular cataract) at the time the patient was included into the study. No attempt was done to wash out anti-glaucoma medication. However, in order to control for the influence of medical or surgical glaucoma therapy, only patients using the same topical antiglaucoma medication in both eyes and throughout the entire follow up period for which stability or progression in visual field damage was evaluated, or patients subjected to filtration surgery prior to this observation period were included.

In each patient a diurnal intraocular pressure (IOP) curve (before arising from bed at 6.00 am, 8.00 am, 11.00 am, 4.00 pm, and 10.00 pm) was obtained in both eyes the day ET-1 was given. Only patients showing no readings above 21 mm Hg were considered for the present analysis.

All patients had typical glaucomatous disc and visual field damage. Only data from patients experienced in visual field testing were considered. After excluding the first fields from the series available, retrospective information for at least five consecutive visual field examinations had to be available in each patient for evaluation of progression. No alteration in treatment during this period was tolerated. The patients had 3 mm or larger pupil diameters when their fields were plotted and fields with poor reliability (fixation loss exceeding 20% and false-positive or false-negative errors exceeding 33%) were not considered.

Visual field examinations had been performed with the program G11 on the Octopus Visual Field Analyzer (Interzeag, Schlieren, Switzerland). The criteria for glaucomatous visual field defects were a cluster of three points (except rim points) in at least one hemifield reduced by 5 dB or greater, and including at least one point reduced by 10 dB or greater; a cluster of two points reduced by 10 dB or...
greater; or three adjacent points on the nasal horizontal meridian that differed by 5 dB or greater from their mirror points on the opposite side of the meridian.

The definition of visual field progression consisted of deepening of an existing scotoma, expansion of an existing scotoma, or a fresh scotoma in a previously normal part of the visual field, in the three last fields of the selected series per eye. A deepening or expansion of an existing scotoma was diagnosed if two adjacent points had declined 10 dB from their original values, and a new scotoma was diagnosed if an alteration meeting the criteria for a visual field defect occurred in a previously normal part of the field. In patients with only one eye showing progressive damage, this eye was selected for further evaluation; when both eyes showed progression, or no progression had occurred in both eyes, one randomly chosen eye was considered for further evaluation.

ET-1 plasma levels were determined by a specific radioimmunoassay, as described by d’Uscio et al. Venous EDTA blood samples (20 ml) were taken after 30 minutes of rest in a supine position at room temperature at about 8.00 am. The blood samples were stored immediately on ice and cooled centrifugation at 4°C was performed for 10 minutes. Plasma was separated at 4°C and kept at −80°C until assay. Extraction was performed by absorption on 300 mg SepPak Vac C18 cartridges (Millipore Ltd, Watford, UK). Columns were preactivated by successive washes with 5 ml of 86% ethanol, 5 ml of sterile distilled water, and 5 ml of 4% acetic acid. A 2 ml plasma sample acidified with 6 ml of 4% acetic acid was then applied on the column with the flow rate of 3 ml/min. The columns were then washed with 18 ml of sterile distilled water, 1.8 ml ethyl acetate, and 18 ml of 24% ethanol in 4% acetic acid before ET was eluted with 86% ethanol in 4% acetic acid. The eluate was dried under nitrogen at 37°C and redissolved in 0.1 ml of assay buffer composed of 0.1% phosphate buffer (pH 7.4), 0.05 mol/l NaCl, 0.1% Triton X-100, 0.02% sodium azide, and 0.1% BSA. The radioimmunoassay of plasma ET was performed using synthetic human/porcine ET-1 (Sigma Chemical Co, St Louis, MO, USA), a rabbit antibody against synthetic ET (Peninsula Laboratories, San Carlos, CA, USA), and 125I-ET-1 (Amersham, Freiburg, Germany). The antibody has 100% cross-reactivity with ET-1, 7% with ET-2 and ET-3, 17% with big endothelin-1, and no cross-reactivity with other peptides. The anti-ET antibody was reconstituted according to the manufacturer’s instructions and then further diluted 1:3.5 with the assay buffer before adding 100 μl to the standards or the reconstituted plasma samples (100 μl) analysed in duplicate. After 24 hours of incubation, 100 μl of 125I-ET-1 (10 to 12×10³ cpm per tube) was added, and incubation was allowed to continue for an additional 24 hours. The separation of bound and free antigen was performed with a second antibody method, and pellets were counted by a gamma counter (Canberra Packard). Reference values (mean (standard deviation)) in our laboratory are 1.42 (SD 0.28) pg/ml for females and 1.67 (SD 0.34) pg/ml for males.

Systemic blood pressure was recorded three times at three minute intervals by an automatic device (Profihomat; Disetronic, Burgdorf, Switzerland) after 30 minutes of rest in a supine position and after blood sampling at the opposite arm. This device measures the blood pressure automatically, using the same principle as the conventional mercury sphygmomanometer, with a cuff and a microphone. The average of the three consecutive blood pressure readings for systolic blood pressure (SBP) and diastolic blood pressure (DBP) were used to calculate the mean arterial blood pressure (MBP) according to the formula: MBP = 2/3 × DBP +1/3 × SBP.

Data are given as mean (standard deviation). Differences between groups regarding age, systemic blood pressure, IOP, follow up period, and the number of visual fields obtained during the follow up period were assessed by means of Student’s t test for independent samples. Fisher’s exact test was used to compare the distribution of female and male patients. Difference in the plasma level of ET-1 between two groups was compared by means of analysis of covariance (ANCOVA) using age, sex, and mean arterial blood pressure as covariates. A p value below 0.05 was considered statistically significant.

RESULTS

Three male and 13 female patients satisfying criteria for progressive visual field damage and four male and 11 female patients with stable visual fields (p = 0.46) were recruited. Mean (SD) age was respectively 66.9 (SD 11.1) and 63.2 (14.5) years (p = 0.43). There were no significant differences between groups with respect to age, SBP, DBP, MBP, IOP follow up period, and number of visual fields obtained during the follow up period (table 1). Furthermore, as shown in table 1, the visual field index “mean defect” (mean (SD)) at baseline for patients with progressive damage and stable visual fields was comparable, but had changed significantly in patients with progressive damage. Treatment of the patients is summarised in table 2. Three patients in each experimental group had filtration surgery prior to the observation period.

Plasma levels of ET-1 at the end of the observation period (see figure 1) were significantly higher in patients with progressive damage (3.47 (0.75) pg/ml; range 2.34–5.17 pg/ml) compared with those with stable (2.60 (SD 0.54) pg/ml; range 1.91–3.45 pg/ml) visual fields (ANOVA: F (1,29) = 13.94281; p = 0.0008). This difference was still significant after controlling for the interaction of sex and including age and MBP as covariates into the model (ANCOVA: F (1,25) = 4.99; p = 0.0367). Sex had a borderline significant effect (ANOVA: F (1,25) = 4.25; p = 0.0497), but the interaction between sex and disease progression was not significant (ANCOVA: F (1,25) = 1.84; p = 0.19).

DISCUSSION

The present study suggests an increased plasma level of ET-1 in primary open angle glaucoma patients with progressive damage when compared with primary open angle glaucoma patients with stable visual fields. This difference was independent of sex, age, and mean blood pressure. Furthermore, the values obtained among patients with a stable visual field were above the reference values established in our laboratory. A possible explanation for these findings could be that ET-1 may contribute primarily to the damaging process in glaucoma, but also remain increased secondarily to the

### Table 1 Clinical parameters of the experimental groups (mean (SD))

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Progressive group</th>
<th>Stable group</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP (mm Hg)</td>
<td>121.9 (18.9)</td>
<td>114.8 (12.3)</td>
<td>0.23</td>
</tr>
<tr>
<td>DBP (mm Hg)</td>
<td>75.6 (14.0)</td>
<td>71.9 (8.0)</td>
<td>0.38</td>
</tr>
<tr>
<td>MBP (mm Hg)</td>
<td>91.0 (15.0)</td>
<td>86.2 (6.4)</td>
<td>0.26</td>
</tr>
<tr>
<td>Follow up (months)</td>
<td>48.4 (16.8)</td>
<td>50.2 (21.6)</td>
<td>0.80</td>
</tr>
<tr>
<td>IOP at baseline (mm Hg)</td>
<td>17.0 (4.3)</td>
<td>16.7 (4.8)</td>
<td>0.84</td>
</tr>
<tr>
<td>MD at baseline (dB)</td>
<td>6.4 (4.6)</td>
<td>5.0 (2.6)</td>
<td>0.30</td>
</tr>
<tr>
<td>MD at the end of follow up (dB)</td>
<td>12.0 (5.2)</td>
<td>4.8 (3.3)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Number of visual fields</td>
<td>6.6 (1.6)</td>
<td>7.4 (2.9)</td>
<td>0.36</td>
</tr>
</tbody>
</table>

SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean arterial blood pressure; IOP, intraocular pressure; MD, visual field index “mean defect”.
damage. An alternative explanation would be that some patients in the group with stable visual fields were in an active stage of their disease, but did not yet satisfy the criteria used to define progression in visual field damage.

The cause for the increased levels of circulating ET-1 in primary open angle glaucoma patients is not clear. One may be tempted to explain the link between systemic levels of endothelin and glaucoma with the association of glaucoma and the primary vasospastic syndrome. High plasma levels of ET-1 have been described in diseases associated with vascular dysregulation such as cerebral vasospasm after subarachnoid haemorrhages, Raynaud’s phenomenon, and ischaemic heart disease. Furthermore, it is believed that in some patients such as in individuals with drug induced coronary spasm, an abnormal response of the vascular endothelium to certain stimuli can lead to abnormally high levels of ET-1 and consequent vasoconstriction. An abnormal endothelial function with an abnormal release of ET-1 after a vasospastic stimulus has been suggested to be related to the genesis of vasospasm in glaucoma. Kaiser et al also demonstrated a faulty regulatory mechanism in the production of ET-1 in normal tension glaucoma: the physiologic increase in plasma ET-1 levels observed when subjects moved from a supine to an upright position was absent in the patients with normal tension glaucoma. Finally, the vascular response to ET-1 has been shown to be enhanced in subcutaneous resistance arteries from patients with NTG, and glaucoma patients with lower blood pressure values react more sensitively to ET-1. As a result of vascular events, ET may in turn have further vascular effects, including ET\textsubscript{A} mediated rapid vasoconstriction and ET\textsubscript{B} induced vasoconstriction mediated by nitric oxide and possibly TNF\textsubscript{a}. but increased ET-1 levels may also exert direct receptor mediated effects on retinal ganglion cells and resident glial cells. Retinal ganglion cell loss in glaucomatous optic neuropathy is associated with a disruption in anterograde axonal transport. Theoretically, this can result either from nerve compression or from ischaemia. However, the effect of direct compression or ischaemia on axonal transport has been suggested to involve the loss of linear microtubule arrays in exposed axons, whereas in glaucoma a rather selective dysregulation of axonal transport seems to occur. It has been hypothesised that mechanisms contributing to the perturbation of anterograde axonal transport could involve ET-1. Indeed, intravitreal ET\textsubscript{A} induces a significant impairment of anterograde axonal transport in retinal ganglion cells, but, interestingly, ET\textsubscript{B} receptor mediated vasoconstriction seems not to be a prerequisite for the effect of ET on axonal transport, and evidence has been shown that the observed perturbation might result from the stimulation of ET\textsubscript{B} receptors. Both receptor types ET\textsubscript{A} and ET\textsubscript{B} are expressed in retinal ganglion cells.

### Table 2 Topical glaucoma treatment

<table>
<thead>
<tr>
<th>Drug</th>
<th>Progressive group</th>
<th>Stable group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timolol</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Betaxolol</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Dorzolamide</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Latanoprost</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Brinzolamide</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Dorzolamide + Timolol</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Dorzolamide + Latanoprost</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Dorzolamide + Brimonidine</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Timolol + Latanoprost</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Timolol + Pilocarpine</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Betaxolol + Brinzolamide</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Alternatively, circulating levels of ET-1 may be linked indirectly to the loss of retinal ganglion cells in glaucoma. It has been shown that, through activation of both ET\textsubscript{A} and ET\textsubscript{B} receptors, ET-1 can induce astrogial proliferation in cultured human optic nerve head astrocytes. It is, therefore, possible that increased ET-1 levels in glaucoma play a role in the astrocye proliferation that occurs in glaucomatous optic neuropathy. Indeed, astrogiosis occurs not only in human glaucomatous optic nerve neuropathy, but also in animals with experimentally increased intraocular pressure. Hypothetically, normal interaction between glia and neurons may be disturbed during astrocytosis, which may enhance the rate of neuronal loss during glaucomatous damage.

The present study cannot conclusively prove the direct implication of ET-1 in the pathogenic process of glaucomatous optic neuropathy. This would require a prospective study with repeated dosing of plasma levels of ET-1 and, ideally, the assessment of the effect of endothelin receptor blockers.

### Authors’ affiliations

M Emre, S Orgül, T Haufschild, J Flammer, University Eye Clinic, Basel, Switzerland

S G Shaw, Department of Clinical Research, University of Berne, Berne, Switzerland

### REFERENCES


![Figure 1](http://bjo.bmj.com/ on April 13, 2017 - Published by group.bmj.com)
Endothelin in progressive glaucoma

Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma

M Emre, S Orgül, T Haufschild, S G Shaw and J Flammer

*Br J Ophthalmol* 2005 89: 60-63
doi: 10.1136/bjo.2004.046755

Updated information and services can be found at:
http://bjo.bmj.com/content/89/1/60

These include:

**References**
This article cites 33 articles, 12 of which you can access for free at:
http://bjo.bmj.com/content/89/1/60#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Angle (1006)
- Glaucoma (988)
- Intraocular pressure (1002)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/